Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients - Takeaways - MDSpire

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

  • By

  • Christian Nelles

  • Moritz Gräf

  • Pascale Bernard

  • Thorsten Persigehl

  • Nils Große Hokamp

  • David Zopfs

  • David Maintz

  • Nicole Kreuzberg

  • Jürgen Wolf

  • Paul J. Bröckelmann

  • Simon Lennartz

  • September 18, 2024

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors significantly improve overall survival and progression-free survival in melanoma and non-small cell lung cancer patients.

  • 2

    Pseudoprogression, an initial increase in tumor burden followed by response, complicates traditional response assessment using RECIST 1.1.

  • 3

    iRECIST was developed to address atypical response patterns like pseudoprogression, providing a standardized approach for evaluating ICI treatment.

  • 4

    Limited evidence exists comparing iRECIST and RECIST 1.1 in real-world settings, despite suggestions of iRECIST's improved evaluation capacity.

  • 5

    This study aims to compare iRECIST and RECIST 1.1 for assessing treatment response in melanoma and NSCLC patients receiving ICI.

Original Source(s)

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

  • by Christian Nelles, Moritz Gräf, Pascale Bernard, Thorsten Persigehl, Nils Große Hokamp, David Zopfs, David Maintz, Nicole Kreuzberg, Jürgen Wolf, Paul J. Bröckelmann, Simon Lennartz

  • September 18, 2024

Related Content

Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Development of a CT-based comprehensive model with deep learning for differentiating pathological types of pulmonary ground-glass nodules